Aquestive Therapeutics, Inc.AQ.STNASDAQ
Loading
EPS Growth Recovery in ProgressRecovering
Percentile Rank59
3Y CAGR-34.7%
5Y CAGR-11.4%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
-34.7%/yr
Quarterly compound
5Y CAGR
-11.4%/yr
Recent deceleration
Percentile
P59
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 9.52% |
| Q3 2025 | -18.45% |
| Q2 2025 | 13.81% |
| Q1 2025 | 7.10% |
| Q4 2024 | 5.62% |
| Q3 2024 | -18.78% |
| Q2 2024 | -1.99% |
| Q1 2024 | 38.62% |
| Q4 2023 | -22.46% |
| Q3 2023 | 0.54% |
| Q2 2023 | 8.14% |
| Q1 2023 | 18.62% |
| Q4 2022 | 34.26% |
| Q3 2022 | 14.89% |
| Q2 2022 | -6.93% |
| Q1 2022 | 6.32% |
| Q4 2021 | 15.85% |
| Q3 2021 | -21.15% |
| Q2 2021 | -11.86% |
| Q1 2021 | 16.83% |
| Q4 2020 | 17.44% |
| Q3 2020 | 14.67% |
| Q2 2020 | -8.54% |
| Q1 2020 | 57.69% |
| Q4 2019 | -30.67% |
| Q3 2019 | -1.32% |
| Q2 2019 | -8.43% |
| Q1 2019 | 59.62% |
| Q4 2018 | 39900.00% |
| Q3 2018 | -99.75% |
| Q2 2018 | -19.05% |
| Q1 2018 | 231.58% |
| Q4 2017 | -65.45% |
| Q3 2017 | -14.06% |
| Q2 2017 | -23.81% |
| Q1 2017 | 50.00% |
| Q4 2016 | 7.69% |
| Q3 2016 | -38.10% |
| Q2 2016 | 21.74% |
| Q1 2016 | 43.75% |